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Abstract
The activation of pro-inflammatory gene programs by nuclear factor-κB (NF-κB) is primarily 
regulated through cytoplasmic sequestration of NF-κB by the inhibitor of κB (IκB) family of 
proteins1. IκBβ, a major IκB isoform, can sequester NF-κB in the cytoplasm2, although its 
biological role remains unclear. While cells lacking IκBβ have been reported3,4, in vivo studies 
have been limited and suggested redundancy between IκBα and IκBβ5. Like IκBα, IκBβ is also 
inducibly degraded, however upon stimulation by LPS, IκBβ is degraded slowly and resynthesized 
as a hypophosphorylated form that can be detected in the nucleus6–11. The crystal structure of 
IκBβ bound to p65 suggested this complex might bind DNA12. In vitro, hypophosphorylated IκBβ 
can bind DNA with p65 and cRel, and the DNA-bound NF-κB:IκBβ complexes are resistant to 
IκBα, suggesting hypophosphorylated, nuclear IκBβ may prolong the expression of certain 
genes9–11. We now report that in vivo IκBβ serves to both inhibit and facilitate the inflammatory 
response. IκBβ degradation releases NF-κB dimers which upregulate pro-inflammatory target 
genes such as tumor necrosis factor-α (TNFα). Surprisingly absence of IκBβ results in a dramatic 
reduction of TNFα in response to lipopolysaccharide (LPS) even though activation of NF-κB is 
normal. The inhibition of TNFα mRNA expression correlates with the absence of nuclear, 
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hypophosphorylated-IκBβ bound to p65:c-Rel heterodimers at a specific κB site on the TNFα 
promoter. Therefore IκBβ acts through p65:c-Rel dimers to maintain prolonged expression of 
TNFα. As a result, IκBβ−/− mice are resistant to LPS-induced septic shock and collagen-induced 
arthritis. Blocking IκBβ might be a promising new strategy for selectively inhibiting the chronic 
phase of TNFα production during the inflammatory response.
To better understand the biological function of IκBβ we decided to study mice lacking the 
IκBβ gene. Homologous recombination was used to delete the majority of the IκBβ coding 
sequences (30–308 aa) including elements essential for binding to NF-κB (Supplementary 
Fig. 2)6,12,13. Absence of IκBβ was confirmed by immunoblotting of mouse embryonic 
fibroblasts (MEFs; Supplementary Fig. 2). Although IκBβ is expressed broadly including in 
hematopoietic organs (Supplementary Fig. 3a), the IκBβ knockout mice breed and develop 
normally without any obvious phenotypic defects.
NF-κB and IκB proteins function in an integrated network and hence reduced expression of 
one component may cause compensatory changes in levels of other proteins 14,15. However, 
expression levels of IκBα, IκBε, p65, RelB, c-Rel, p105 and p100 were unaffected in 
IκBβ−/− mice (Supplementary Fig. 3b). Increased NF-κB activity has been observed in other 
IκB knockouts16–18, and increased basal NF-κB reporter activity was observed in IκBβ−/− 
MEFs (Fig. 1a). Electrophoretic mobility shift assays (EMSA) demonstrated increased basal 
NF-κB activity in IκBβ−/− cells (60%) (Supplementary Fig. 3c). Conversely, overexpression 
of IκBβ inhibits NF-κB activation (Supplementary Fig. 3d). Thus IκBβ inhibits NF-κB and 
degradation or loss of IκBβ contributes to NF-κB activity. NF-κB reporter assays reveal that 
absolute NF-κB activity in response to LPS, IL-1β or TNFα is slightly higher in the IκBβ−/− 
than wild type (WT) cells (Fig. 1a). However, the kinetics of NF-κB activation by EMSA, 
and the pattern of IκB degradation by immunoblotting, in cells stimulated with LPS, IL-1β 
or TNFα were not demonstrably different in IκBβ−/− cells (Supplementary Fig. 4). Thus, 
loss of IκBβ results in a modest elevation in basal NF-κB activity, while inducible NF-κB 
activation is relatively unaffected.
NF-κB regulates the expression of many genes, in particular those involved in inflammation 
and immune responses19. To determine whether IκBβ has a role in the inflammatory 
response, IκBβ−/− and IκBβ−/+ mice were challenged with LPS. Surprisingly, IκBβ−/− mice 
were significantly resistant to the induction of shock (Fig. 1b). We therefore examined the 
serum levels of the key acute phase cytokines TNFα, IL-1β and IL-620 following LPS 
injection. In wild type mice TNFα production peaked 1 hour after LPS injection, while IL-6 
and IL-1β production peaked around 2 hours, in agreement with previous studies21. 
Although serum IL-6 and IL-1β were reduced (~25%) in the IκBβ−/− mice, the reduction of 
TNFα levels (>70%) was more striking (Fig. 1C). As the peak of serum TNFα precedes that 
of IL-1β and IL-6, it is likely that the reduction of IL-1β and IL-6 is secondary. As 
monocytes and macrophages are major sources for systemic TNFα, we analyzed LPS 
induced cytokines in thioglycollate-elicited peritoneal macrophages (TEPM). While 
equivalent macrophage populations were obtained from the mice (Supplementary Fig. 5a), 
TNFα, but not IL-6, production was drastically reduced in IκBβ−/− TEPM (Fig. 1d).
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To understand how IκBβ affects TNFα synthesis we examined each step of TNFα 
production. Secreted TNFα was detectable by ELISA after 2 hours of LPS stimulation and 
by 4 hours was significantly impaired in IκBβ−/− TEPM (Fig. 2a). IL-6 production was 
equivalent (Fig. 2a). We examined the level of pro-TNFα by intracellular FACS and found 
there was very little pro-TNFα detected in the IκBβ−/− TEPMs even after 8 hours of LPS 
stimulation (Fig. 2b). The average amount of pro-TNFα produced was 2–3 fold higher in 
WT compared to IκBβ−/− TEPM (Fig. 2c). Consistent with this difference in protein levels, 
steady-state TNFα was decreased 2–6 fold in the IκBβ−/− TEPM compared to WT cells 
(Fig. 2d). Although TNFα mRNA is known to be regulated22,23, there was no difference in 
TNFα mRNA stability between WT and IκBβ−/− TEPM (Supplementary Fig. 5b). 
Therefore, IκBβ promotes TNFα transcription.
To understand how IκBβ affects TNFα transcription, we investigated which NF-κB subunits 
were associated with IκBβ in macrophages. It is known that IκBβ associates with p65:p50 
and c-Rel:p50 complexes24 through direct binding to p65 and c-Rel but not p506. However, 
we found that IκBβ could be immunoprecipitated only with p65 and c-Rel, but not p50 (Fig. 
3a). Both immunoprecipitations with anti-p65 and anti-c-Rel antibodies pull down IκBβ, 
IκBα and p50. Thus, there are p65:p50 and inducible c-Rel:p50 complexes that are 
associated with IκBα or other IκBs, but not IκBβ. Reciprocal immunoprecipitation of p65 
with c-Rel and both p65 and c-Rel with IκBβ suggests a p65:c-Rel heterodimer associated 
with IκBβ (Fig. 3b). To demonstrate the association of IκBβ with p65:c-Rel, we performed 
sequential immunoprecipitations by first immunoprecipitating IκBβ and then 
immunprecipitating the eluted IκBβ complexes with anti-c-Rel antibody. The presence of 
p65 in the anti-c-Rel immunoprecipitate confirms the presence of IκBβ:p65:c-Rel complex 
(Fig. 3c). The IκBβ:p65:c-Rel complex was found in nuclear extracts suggesting that this 
could be a transcriptionally active complex. We had previously reported10 that IκBβ exists 
in two phosphorylation states: a hyperphosphorylated state in quiescent, unstimulated cells, 
and a hypophosphorylated newly synthesized state in LPS stimulated cells (Fig. 3c and 
Supplementary Fig. 5a). In the co-immunoprecipitation experiments shown here we found 
that both forms of IκBβ can bind p65 and c-Rel, although the hypophosphorylated form 
predominates in the IκBβ:p65:cRel complex following LPS stimulation.
There are four κB sites upstream of TNFα coding region, three of which are crucial for NF-
κB dependent TNFα expression25. Therefore, we performed chromatin immunoprecipitation 
(ChIP) with anti-p65, anti-c-Rel and anti-IκBβ antibodies in RAW264.7 cells and monitored 
the region encompassing these three κB sites. Following LPS stimulation, TNFα promoter 
region DNA is enriched by p65, c-Rel and IκBβ antibodies by 56, 70 and 7 fold respectively 
(Fig. 3d). In contrast, IκBβ is not recruited to the IL-6 promoter following LPS stimulation 
while p65 and c-Rel are recruited as expected (Fig 3d). Recruitment of p65, c-Rel and IκBβ 
to the TNFα promoter was also confirmed in WT bone marrow derived macrophages 
(BMDM; Fig 3e). In the IκBβ−/− BMDM, both p65 and c-Rel are recruited normally to the 
TNFα promoter. However, when we performed immunoprecipitation with anti-p65, c-Rel 
and IκBβ are pulled down in WT but not IκBβ−/− BMDM (Fig. 3f). Therefore, p65 and c-
Rel fail to form a stable complex in IκBβ−/− cells. Thus, the p65 and c-Rel recruited to the 
TNFα promoter in IκBβ−/− cells is not a p65:c-Rel complex. These data suggest that optimal 
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TNFα transcription requires a ternary complex of IκBβ:p65:c-Rel binding to the TNFα 
promoter.
In order to identify the κB site for p65:c-Rel binding we performed EMSAs using the three 
κB sites from the TNFα promoter as probes (κB2, κB2a and κB3, Supplementary Fig. 5b). 
We identified two distinct gel-shift patterns. κB3 and κB2a show two major bands (only 
κB3 is shown in Fig. 3g) while κB2 shows three major inducible shift bands. The 
components of the bands were identified by super-shift assay (Fig. 3g, right panel). The top 
band in the κB2 gel-shift is mostly p65:c-Rel. Interestingly, the κB2 site possesses features 
predicted to favor p65:c-Rel binding (Supplementary Fig. 5c). Similar κB binding sites in 
the CD40 and CXCL1 promoters also demonstrated coordinate recruitment of IκBβ, p65, 
and c-Rel (Supplementary Fig. 5d). Furthermore, deletion of the κB2 site from a TNFα 
promoter reporter abrogated IκBβ-dependent reporter gene expression (Supplementary Fig. 
6). In IκBβ−/− BMDM, the p65:c-Rel complex binding to theκB2 in EMSA assays is 
missing (Fig. 3h), in agreement with the immunoprecipitation result. Therefore optimal 
TNFα transcription requires a p65:c-Rel complex, stabilized by hypophosphorylated IκBβ, 
binding to the κB2 site in the TNFα promoter.
To identify other genes affected by IκBβ deficiency, we examined gene expression profiles 
in WT and IκBβ−/− BMDM. As expected, TNFα and IκBβ are among the genes whose 
expression is affected by IκBβ deficiency while IL-6 and IL-1β are not affected (Fig. 4a). Of 
the genes whose expression is reduced in the IκBβ−/− cells we identified 14 with expression 
patterns resembling TNFα (Fig. 4b). The expression of these genes was also reduced in p65, 
c-Rel or p65/c-Rel knock-out fetal liver macrophages suggesting that LPS-induced 
expression of these genes might depend on a mechanism similar to TNFα (data not shown). 
The expression of TNFα, IL-1α, IL-6 and IL-1β in response to LPS was further examined by 
RNase protection (Fig. 4c) and qRT-PCR assays (Supplementary Fig. 7) demonstrating that 
the reduction in persistent expression of TNFα in IκBβ−/− cells is unique. Reduced IL12b 
mRNA and protein secretion in the knockout TEPM was confirmed by qRT-PCR (Fig. 4d) 
and ELISA (Fig. 4e). Notably, transcription of IL12b, which has a κB site similar to κB2 of 
TNFα (Supplementary Fig. 5c), has previously been shown to require c-Rel and be partially 
dependent on p6526. Thus, only a select group of NF-κB dependent genes are diminished 
similarly to TNFα upon IκBβ deletion. As TNFα plays a key role in inflammation, we 
wanted to test whether IκBβ−/− deletion would affect the course of inflammatory diseases.
Rheumatoid arthritis (RA) is a common inflammatory disease with morbidity resulting from 
ongoing release of pro-inflammatory cytokines, including TNFα, and consequent 
destruction of joint tissue27. Previous studies have shown that NF-κB plays a key role in 
mouse models of arthritis and blocking NF-κB has a dramatic effect in preventing 
disease28,29. RA can also be effectively treated by anti-TNFα therapies, although there are 
significant side-effects30. The ability to block only persistent TNFα expression would be 
therapeutic without blocking beneficial TNFα responses including the expression of innate 
immune response genes. We therefore tested whether the lack of IκBβ altered the course of 
collagen-induced arthritis (CIA), a well-characterized mouse model of RA.
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To induce CIA we immunized DBA/1J mice with bovine type II collagen. IκBβ−/− mice 
displayed delayed onset, lower incidence and decreased severity of CIA (Fig. 4f and 
Supplementary Fig. 8). Inflammation in the WT mice extended from the paws and digits to 
the ankle joints and distally through the limb (data not shown). In contrast, IκBβ−/− mice 
showed minimal visual signs of paw and joint swelling (Supplementary Fig. 8). Serum 
TNFα was markedly decreased in IκBβ−/− mice while other pro-inflammatory cytokines 
were not significantly affected (Fig. 4g and Supplementary Fig. 9). Therefore the absence of 
IκBβ limits the progression and severity of arthritis by reducing the chronic production of 
TNFα.
The results presented above demonstrate a dual role for IκBβ: during the early stages of LPS 
stimulation, NF-κB complexes released by IκBβ degradation contribute to the initial 
expression of TNFα (Supplementary Fig. 1). Then, newly synthesized hypophosphorylated 
IκBβ facilitates the formation of IκBβ:p65:c-Rel complexes which selectively bind to the 
κB2 site in the TNFα promoter augmenting transcription. As shown in the gene chip and 
RNAse protection assays, this is a relatively selective function and IκBβ−/− mice are, 
therefore, otherwise normal. Hence targeting IκBβ might be a promising new strategy to 
treat chronic inflammatory diseases such as arthritis.
Methods summary
Mice
IκBβ deficient mice were generated by standard homologous recombination in the CJ7 ES 
cell line using a targeting construct that replaced exon 2 through exon 5 with a G418-
resistance gene. Screened ES cell clones were injected into blastocysts derived from 
C57BL/6 mice gave rise to IκBβ−/+/IκBβ+/+ chimeras. Germline transmission of the 
disrupted allele was obtained and verified by Southern blotting and PCR, and mice were 
backcrossed at least 10 generations onto the B57BL/6 background. Mice were backcrossed 
at least 8 generations onto the DBA background for CIA experiments. Mice were 
maintained in pathogen-free animal facilities at Yale Medical School.
Cells
WT and IκBβ knockout MEFs were generated from E12.5 embryos following timed 
breeding of IκBβ+/− animals. TEMPs were obtained from 6- to 8-week-old littermate mice 
three days after intraperitoneal injection with thioglycollate. BMDM were harvested by 
standard protocols and differentiated with 30% L929 supernatant-conditioned media.
Biochemistry
Cell fractionation, western blotting, EMSA, and immunoprecipitations were performed as 
previously described unless otherwise indicated6.
LPS-induced shock
LPS-induced shock was tested by intraperitoneal injection of 50 ug/g body weight LPS and 
monitoring for survival. In a separate identical experiment, the mice were bled at 1 hr and 2 
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hr after LPS treatment and the concentration of TNF-α, IL-6 and IL-1β in the serum was 
measured by ELISA.
Intracellular cytokine analysis
Pro-TNFα levels were analyzed in LPS stimulated TEMPs cells following LPS stimulation 
and brefeldin-A treatment. TNFα was detected following cell permeabilization using 
standard intracellular cytokine staining and flow cytometry.
qRT-PCR
RNA expression was quantified by quantitative two-step SYBR real-time RT-PCR, and 
relative mRNA levels were obtained by normalizing the readout for each specific gene by 
that of β-actin.
Microarray Analysis
Microarrays for gene expression analyses were performed on BMDMs stimulated with LPS 
and Affymetrix Mouse genome 430A 2.0 arrays as per the manufacturers protocol.
Full Methods and any associated references are available in the online version of the paper 
at www.nature.com/nature.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mice lacking IκBβ are resistant to LPS-induced endotoxin shock
a, WT and IκBβ−/− MEF cells transfected with pBIIx-luc reporter and Renilla luciferase 
vectors were treated with TNFα, IL-1β or LPS for 4 hours and analyzed for luciferase 
activity. Results are expressed as relative luciferase unit (RLU) normalized by Renilla 
luciferase activity; error bars indicate ±s.d (n=3). b, Age and sex matched mice received 
intra-peritoneal injection of LPS and survival rates were scored every 8 hours for 3 
days(n=7). c, Serum TNFα, IL-6 and IL-1β 1 hour and/or 2 hour after IP injection of LPS 
was examined by ELISA; error bars indicate ±s.d (n=5). d, TEPMs from littermate mice 
were treated for 20 hours with LPS as indicated, and TNFα and IL-6 in the media was 
determined by ELISA; error bars indicate ±s.d (n=3).
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Figure 2. Deficient TNFα transcription in IκBβ−/− macrophages
a, TEPMs from littermate WT and IκBβ−/− mice were treated with LPS and secreted TNFα 
and IL-6 were determined by ELISA; error bars indicate ±s.d. (n=3). b, TEMPs from 
littermate mice were treated as in (a) in the presence of Brefeldin A, and intracellular pro-
TNFα was examined with flow cytometry. c, Intracellular pro-TNFα production was 
examined as in B with macrophages isolated from 3 pairs of littermate mice; error bars 
indicate ±s.d. d, TEMPs were stimulated with LPS as in A and relative TNFα mRNA level 
was determined by qRT-PCR; error bars indicate ±s.d (n=3).
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Figure 3. IκBβ is recruited to the promoter of TNFα together with P65 and c-Rel
a,b, Raw264.7 were stimulated with LPS and immunoprecipitated (IP) with anti-IκBβ (a), 
anti-p65 (b) or anti-c-Rel (b) antibodies and immunoblotted (IB) as indicated. c, LPS-
stimulated Raw264.7 lysates were immunoprecipitated with anti-IκBβ; eluted with IκBβ 
peptide; immunoprecipitated with anti-c-Rel antibody; and immunoblotted as indicated. d, 
Raw264.7 lysates were subjected to ChIP as indicated and analyzed by qPCR targeting 
TNFα and IL-6 promoter κB sites; error bars indicate ±s.d (n=3). e, ChIP was performed as 
in (d) on WT and IκBβ−/− BMDM treated with LPS for 2 hours; error bars indicate ±s.d 
(n=3). f, BMDM treated as in (e) were immunoprecipitated with anti-p65 antibody. g, 
RAW264.7 were treated with LPS and nuclear extracts were subjected to EMSA TNFα κB3 
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or κB2 probes. Super shifts were performed using cells stimulated for 1hr. h, BMDM were 
treated with LPS and EMSA and supershifts with the κB2 probe were performed as in (g).
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Figure 4. IκBβ knockout selectively affects only certain LPS responsive genes and attenuates 
collagen induced arthritis
a, LPS responsive genes whose expression is either down-regulated, up-regulated or 
unchanged in IκBβ−/− BMDM. b, Host-pathogen interaction genes that are IκBβ dependent 
and LPS responsive genes whose expression pattern resembles TNFα. c, RNase protection 
assay using WT and IκBβ−/− BMDM stimulated with LPS. d, IL-12b relative mRNA level 
determined by qRT-PCR in samples prepared as in (c); error bars indicate ±s.d. (n=3). e, 
ELISA for IL-12p40 secreted from WT and IκBβ−/− TEMP stimulated with LPS for 20 
hours; error bars indicate ±s.d. f, Arthritis clinical scoring in WT (n=10) or IκBβ−/− (n=8) 
DBA mice; error bars indicate ±SEM. g, Serum TNF-α, IL-1β, and IL-6 levels in WT or 
IκBβ−/− DBA mice in (f); error bars indicate ±SEM.
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